临床普外科电子杂志 ›› 2025, Vol. 13 ›› Issue (1): 21-.

• • 上一篇    下一篇

比较肝动脉插管化疗栓塞术与肝动脉灌注化疗术在原发性肝癌患者治疗中的应用效果及安全性#br#

  


  • 出版日期:2025-01-01 发布日期:2025-03-12

Comparison of the effi cacy and safety of transcatheter arterial chemoembolization and hepatic artery infusion chemotherapy in the treatment of primary liver cancer patients

  • Online:2025-01-01 Published:2025-03-12

摘要: 目的 探讨肝动脉插管化疗栓塞术(transcatheter arterial chemoembolization,TACE)与肝动脉灌注化疗术(hepatic artery infusion chemotherapy,HAIC)在原发性肝癌患者治疗中的应用效果对比。方法 选取 2023 年 1 月至 2024 年 1 月前海人寿广州总医院收治的 80 例原发性肝癌患者,按随机数字表法分为对照组和观察组,各 40 例。对照组采取 HAIC,观察组采用 TACE。对比两组临床治疗效果、肿瘤标志物、肝功能指标及安全性。结果 观察组总有效率为 95.00%(38/40),高于对照组 [80.00%(32/40)],差异有显著性(P < 0.05)。治疗前,两组患者的肿瘤标志物及肝功能指标水平无显著差异(P > 0.05);治疗后,观察组患者的血清癌胚抗原为(8.17±1.23)μg/L、糖类抗原 125 为(23.45±3.52)U/ml、谷草转氨酶为(51.66±5.24)U/L、谷丙转氨酶为(69.36±7.22)U/L、总胆红素为(15.79±2.67)μmol/L,显著低于对照组 [ 分别为(9.65±1.14)μg/L、(28.97±3.29)U/ml、(62.70±6.35)U/L、(78.95±9.13)U/L、(19.45±3.06)μmol/L],差异均有显著性(P < 0.05)。两组患者的并发症发生率相比,差异无显著性(P > 0.05)。结论 与 HAIC 相比,TACE 治疗原发性肝癌可获得更好的疗效,能降低肿瘤标志物,改善肝功能,安全性高。

关键词: 原发性肝癌, 肝动脉插管化疗栓塞术, 肝动脉灌注化疗术, 效果

Abstract:

Objective To compare the application eff ects of transcatheter arterial chemoembolization (TACE) and hepatic artery infusion chemotherapy (HAIC) in the treatment of primary liver cancer patients. Method 80 patients with primary liver cancer admitted to Guangzhou General Hospital of China Life Insurance from January 2023 to January 2024 were selected and randomly divided into two groups, with 40 patients in each group, using a random number table method. The control group was treated with HAIC, while the observation group was treated with TACE. Compare the clinical treatment effi cacy, tumor markers, liver function indicators, and safety between two groups. Result The total eff ective rate of the observation group was 95.00% (38/40), which was higher than that of the control group [80.00%(32/40)], and the diff erence was signifi cant(P < 0.05). Before treatment, there was no signifi cant diff erence in the levels of tumor markers and liver function indicators between the two groups of patients(P > 0.05); After treatment, the serum carcinoembryonic antigen of the observation group patients was (8.17±1.23)μg/L, carbohydrate antigen 125 was (23.45±3.52)U/ml, aspartate aminotransferase was (51.66±5.24)U/L, alanine aminotransferase was (69.36±7.22)U/L, and total bilirubin was (15.79±2.67)μmol/L, which were significantly lower than those of the control group [(9.65±1.14)μg/L, (28.97±3.29)U/ml, (62.70±6.35)U/L, (78.95±9.13)U/L, (19.45±3.06)μmol/L, respectively], and the diff erences were signifi cant (P < 0.05). There was no signifi cant diff erence in the incidence of complications between the two groups of patients (P > 0.05). Conclusion Compared with HAIC, TACE treatment for primary liver cancer can achieve better effi cacy, reduce tumor markers, improve liver function, and has high safety.

Key words: Primary liver cancer, Transcatheter arterial chemoembolization, Hepatic artery infusion chemotherapy, Eff ect